Related by context. All words. (Click for frequent words.) 63 systolic dysfunction 63 nonischemic 62 LV dysfunction 62 Hypotension 62 β blockers 62 HIV HCV coinfected 61 GH deficiency 61 olmesartan 61 left ventricular dysfunction 61 antiarrhythmic drug 61 cytopenias 61 choroidal vasculopathy 61 postoperative AF 61 sinus node dysfunction 61 acromegalic patients 60 antiarrhythmic 60 angiographically 60 atrioventricular block 60 serum retinol 60 AST ALT 60 corrected QT interval 60 etomidate 60 prednisone prednisolone 60 elevated IOP 60 liver histology 60 repolarization 60 artery stenosis 60 Kinoid 60 vasodilators 59 afterload 59 overt nephropathy 59 thromboembolic 59 T1DM 59 plasma pharmacokinetics 59 hemodilution 59 cardiac repolarization 59 sinus bradycardia 59 carotid IMT 59 left ventricular systolic 59 torsade de pointes 59 preterm neonates 59 Subgroup analysis 59 androgen deprivation 59 thrombotic complications 59 depressive symptomatology 59 serum urate levels 59 inotropic 59 hyperacute 59 thromboembolic complications 59 myocardial fibrosis 59 silent ischemia 59 hypoperfusion 59 beta blocker therapy 59 cardioprotection 59 hyperalgesia 59 paroxysmal AF 59 bullous 59 antiphospholipid antibodies 59 rFVIIa 59 HeFH 59 colorectal adenoma 59 intravenous cyclophosphamide 59 hyperprolactinemia 58 salmeterol HFA MDI 58 myocardial dysfunction 58 osteopenic 58 cerebral vasospasm 58 NYHA functional class 58 autonomic dysfunction 58 coronary stenosis 58 cerebrovascular events 58 symptomatic paroxysmal AF 58 isoproterenol 58 CTEPH 58 cardiotoxic 58 thiopurine 58 LVSD 58 G6PD deficiency 58 neutrophil counts 58 arteriography 58 paricalcitol 58 IOP lowering 58 adrenal suppression 58 undergoing CABG 58 nonfatal MI 58 ventricular arrhythmia 58 serum calcium levels 58 clomipramine 58 urolithiasis 58 cTnI 58 dysfunction LVSD 58 adrenal function 58 NSTEMI 58 Heavy menstrual bleeding 58 VT VF 58 extrapyramidal symptoms 58 eplerenone 58 non valvular atrial 58 sotalol 58 thrombocytopenic 58 CYP #A# 58 metabolic disturbances 58 parkinsonian symptoms 58 BEXXAR Therapeutic Regimen 58 clinically meaningful improvement 58 cardiac insufficiency 58 ß blockers 57 proliferative retinopathy 57 elevated LDH 57 subclinical atherosclerosis 57 riociguat 57 rebleeding 57 nadolol 57 ICD shocks 57 endogenous opioid 57 sitaxsentan 57 euthyroid 57 gastric carcinoma 57 polytherapy 57 symptomatic intracranial 57 salmeterol fluticasone 57 LV ejection fraction 57 hippocampal atrophy 57 haematological toxicity 57 AGHD 57 Torsades de Pointes 57 mitral stenosis 57 glomerular filtration 57 nonvertebral fracture 57 LVEF 57 neovascularisation 57 multivessel disease 57 intraventricular 57 leucopenia 57 bioavailable testosterone 57 postoperative complication 57 glycated hemoglobin levels 57 antithrombotic therapy 57 coagulopathy 57 histologic subtype 57 thyroid carcinoma 57 T2DM 57 coadministration 57 mixed hyperlipidemia 57 cranial irradiation 57 vaso occlusive 57 potentiation 57 myocyte 57 Vitamin B# deficiency 57 milrinone 57 normotensive 57 coronary artery occlusion 57 ventricular tachycardia VT 57 periprocedural 57 platelet inhibitor 57 #mmHg [001] 57 intracerebral haemorrhage 57 secondary hyperparathyroidism 57 atherothrombotic events 57 tachyarrhythmias 57 haematologic 57 preserved ejection fraction 57 dyslipidaemia 57 dose atorvastatin 57 Febrile neutropenia 57 beta interferons 57 neurocognitive function 57 posttransplant 57 severe exacerbations 57 vasopressor 57 ventricular myocardium 57 QT interval prolongation 57 intratumoral 57 akinesia 57 antithrombotic therapies 57 adrenal insufficiency 57 hematologic toxicity 57 atherothrombotic disease 57 arterial calcification 57 cerebral ischemia 57 Calcium intake 56 prostate cancer PCa 56 dexrazoxane 56 airflow limitation 56 hyperhomocysteinemia 56 unfavorable cytogenetics 56 ischemia induced 56 neurocognitive deficits 56 thyrotropin 56 plasma renin activity 56 lenalidomide dexamethasone 56 systemic corticosteroid 56 hsCRP levels 56 loop diuretics 56 pouchitis 56 angiotensin converting enzyme inhibitors 56 hypoglycemic episodes 56 aminotransferases 56 bezafibrate 56 arrhythmogenic 56 calcium antagonists 56 Exacerbation 56 perioperatively 56 acute aortic dissection 56 chronic thromboembolic pulmonary 56 serum lipid 56 Helicobacter pylori eradication 56 CIMZIA TM certolizumab pegol 56 carotid stenosis 56 serum phosphate levels 56 subclinical hypothyroidism 56 pericardial effusion 56 left ventricular hypertrophy 56 bronchial hyperresponsiveness 56 clinically evaluable 56 pamidronate 56 lesional 56 serum parathyroid hormone 56 onset diabetes mellitus 56 primary aldosteronism 56 ventricular fibrillation VF 56 HF hospitalization 56 nephrotoxicity 56 antiresorptive 56 IPAH 56 symptomatic VTE 56 Sjögren syndrome 56 platelet inhibition 56 beta adrenergic 56 NPH insulin 56 variant angina 56 ALT elevations 56 inotropes 56 erythropoietic 56 diabetic kidney 56 adrenalectomy 56 stratifying patients 56 vessel occlusion 56 PGTC seizures 56 reinfarction 56 antiarrhythmics 56 OSAHS 56 cytogenetic abnormalities 56 lymphopenia 56 lethal arrhythmias 56 AAT deficiency 56 nasal polyposis 56 nondiabetic patients 56 proliferative diabetic retinopathy 56 timepoints 56 ovarian carcinoma 56 QTc intervals 56 hepatic fibrosis 56 diastolic dysfunction 56 IL 1ß 56 pulmonary toxicity 56 bisoprolol 56 Statin therapy 56 labetalol 56 myocardial infarction MI 56 aortic regurgitation 56 cardiomegaly 56 NIHSS score 56 asthma exacerbation 56 recurrent ischemia 56 benazepril 56 obstructive CAD 56 ventricular dysfunction 56 serum phosphate 56 airflow obstruction 56 coronary stenoses 56 teriflunomide 56 atherothrombotic 56 cardiac conduction 56 plasminogen activators 56 intact parathyroid hormone 56 isolated systolic hypertension 56 carotid artery stenosis 56 NYHA Class II 56 nicardipine 56 TT genotype 56 coagulation abnormalities 56 mycophenolate 56 ejection fractions 56 ATACAND 56 thromboembolic events 56 ventricular tachyarrhythmia 56 mechanical dyssynchrony 55 antioxidant supplementation 55 glitazone 55 IDDM 55 Chronic pancreatitis 55 recurrent DVT 55 renal scarring 55 hepatic encephalopathy HE 55 myocardial infarction stroke 55 β blocker 55 D dimer 55 syncope fainting 55 gastrointestinal perforation 55 thrombophilia 55 sustained ventricular tachycardia 55 failure NYHA 55 cardiac abnormalities 55 clinically meaningful reductions 55 relapsed MM 55 BENICAR HCT 55 unstable angina UA 55 catecholamine 55 carotid artery blockage 55 antiarrhythmic drugs 55 nimodipine 55 recurrent VTE 55 alanine aminotransferase ALT 55 canakinumab 55 pheochromocytoma 55 thiazide diuretic 55 dissolving blood clots 55 systemic hypotension 55 intravascular volume 55 dysrhythmias 55 thyrotoxicosis 55 poor metabolizers 55 chronic LBP 55 hypercalciuria 55 myocardial ischemia 55 prolonged QT interval 55 metoprolol tartrate 55 serum ferritin 55 neuroleptic drugs 55 antiandrogen 55 cystoid macular edema 55 Stent thrombosis 55 serum sodium levels 55 intracerebral 55 hepatic enzyme 55 perfusion defects 55 HSCT 55 cortisol secretion 55 electrophysiologic 55 recurrent UTI 55 ADPKD 55 aldosterone antagonist 55 Clinically significant 55 atorvastatin #mg 55 de novo AML 55 corticosteroid therapy 55 elevated troponin 55 intravitreal bevacizumab 55 systolic function 55 maximal doses 55 reteplase 55 recurrent miscarriage 55 serum calcium 55 #HT#A receptor 55 carcinoids 55 microvascular complications 55 beta adrenergic receptor 55 cirrhotic 55 decompensated heart failure 55 ventricular remodeling 55 hypovolemia 55 PSA nadir 55 hypertensives 55 retrograde ejaculation 55 hepatocellular carcinomas 55 NNT = 55 imatinib therapy 55 asymptomatic carotid stenosis 55 macroalbuminuria 55 esophageal perforation 55 lipid parameters 55 LHRH agonists 55 Severe Primary IGFD 55 subclinical 55 LNG IUS 55 aldosterone antagonists 55 genotypic resistance 55 neurologic sequelae 55 piroxicam 55 moderate renal impairment 55 BPH LUTS 55 concomitant AEDs 55 anemia hemoglobin 55 antidiabetic drugs 55 concomitant medications 55 PLX STROKE targeting 55 recurrent venous thromboembolism 55 angiotensin converting enzyme inhibitor 55 NNRTI resistance 55 hematopoietic cancers 55 VTE prophylaxis 55 baroreflex sensitivity 55 hyperparathyroidism 55 Angioedema 55 leukocytosis 55 antiarrhythmic medications 55 coronary blockages 55 macrovascular disease 55 hypotensive 55 psychiatric comorbidities 55 bacterial prostatitis 55 paroxysmal atrial fibrillation 55 VAPRISOL 55 HIV lipodystrophy 55 diabetes mellitus DM 55 thrombotic events 55 CVD mortality 55 hyperkalemia 55 invasive candidiasis 55 CP CPPS 55 nontraumatic 55 noncardiac 55 renal dysfunction 55 neuroleptic 55 paroxetine sertraline 55 MACCE 55 intravenous diuretics 55 QVAR R 55 induce orthostatic hypotension 55 hypopituitarism 55 albumin excretion 55 atherogenic dyslipidemia 55 inhaled budesonide 55 independent prognostic marker 55 intracranial 55 LVNC 55 Primary endpoints 55 metabolic acidosis 55 relapsed AML 55 eosinophil count 55 systolic hypertension 55 troponin T 55 resynchronization therapy 55 parasitemia 55 acute decompensation 55 hydroxy vitamin D 55 hemoglobin A1c HbA1c 55 malignant neoplasm 55 detrusor overactivity 55 cardiac dysfunction 55 perioperative morbidity 55 airway hyperresponsiveness 55 hypercholesterolaemia 55 p = .# [002] 55 upper gastrointestinal bleeding 55 MULTAQ 55 eptifibatide 55 valvular disease 55 anticholinergic agents 55 aortic valve stenosis 55 cerebral infarction 55 valve regurgitation 55 fluvastatin 55 simvastatin ezetimibe 55 creatinine levels 55 asystole 55 serum homocysteine 55 serum estradiol 55 periprocedural MI 55 levodopa carbidopa 55 Tasigna prolongs 55 reperfusion injury 55 prostate carcinoma 55 allogeneic HSCT 55 perfusion abnormalities 55 NATRECOR R 55 Barrett esophagus BE 55 Acute Coronary Syndromes ACS 55 QTc prolongation 55 lactic acidosis 55 Dacogen decitabine 55 tachycardias 55 PAOD 55 cerebral oxygenation 55 caspofungin 55 premorbid 55 fractional shortening 55 verapamil 55 airway responsiveness 54 tumor necrosis 54 tardive dyskinesia TD 54 P = .# 54 mutated K ras 54 inhibitor RG# 54 intracranial stenosis 54 prolonged QT intervals 54 prospectively defined 54 CC genotype 54 FluCAM arm 54 microvascular disease 54 QT intervals 54 potassium sparing diuretics 54 pharmacokinetic interactions 54 hypercalcemia 54 heparin induced thrombocytopenia 54 cardiac troponin 54 MADRS score 54 microsatellite instability 54 hyperoxaluria 54 tamponade 54 serum PTH 54 Akathisia 54 ERK activation 54 plasma lipids 54 threatening ventricular arrhythmias 54 malignant ascites 54 pleiotropic effects 54 aortic atherosclerosis 54 oxygen saturations 54 growth hormone secretion 54 penetrance 54 cardiac tamponade 54 Endothelial dysfunction 54 transaminase elevations 54 chronic urticaria 54 carotid atherosclerosis 54 parkinsonism 54 nonadherence 54 prostate cancer CaP 54 mu opioid 54 Losartan 54 glycated hemoglobin HbA1c 54 vasodilatation 54 Inhaled nitric oxide 54 serum creatinine levels 54 microcirculatory 54 aspirin clopidogrel 54 chronicity 54 endoleak 54 lipid lowering drugs 54 hMG 54 benign prostate 54 heterozygotes 54 gastrointestinal GI bleeding 54 myopathy rhabdomyolysis 54 thrombo embolic 54 antiangiogenic therapy 54 % Confidence Interval 54 enteroviral infection 54 arterial thromboembolic events 54 femoral neck fracture 54 onset seizures 54 neurologic dysfunction 54 flecainide 54 cardioembolic stroke 54 laboratory abnormalities 54 aortic insufficiency 54 ischemic cardiomyopathy 54 cerebral perfusion 54 acute myocardial infarction AMI 54 paroxysmal supraventricular tachycardia 54 renal insufficiency 54 revascularisation procedures 54 oral antidiabetes drugs 54 mucosal inflammation 54 symptomatic intracranial hemorrhage 54 hypovolemic 54 PPAR gamma agonists 54 atrial tachyarrhythmias 54 MEVACOR 54 Vorapaxar 54 teratogenicity 54 oral antiplatelet therapy 54 radiotherapy RT 54 Lipitor #mg 54 hypokalemia 54 PNH patients 54 cryptogenic stroke 54 beta carotene supplementation 54 cytopenia 54 renal artery stenosis 54 hemodialysis patients 54 pulmonary dysfunction 54 cardioprotective effects 54 hydroxyvitamin D concentrations 54 pretransplant 54 PHPT 54 silent myocardial ischemia 54 plasma triglycerides 54 streptokinase 54 arterial thrombosis 54 Procoralan 54 valvular heart disease 54 hypertrophic cardiomyopathy HCM 54 dihydropyridine 54 thienopyridine 54 glycosylated hemoglobin HbA1c 54 venlafaxine Effexor 54 Adjunctive 54 multivariable analysis 54 tenecteplase 54 vasospasm 54 angiotensin receptor blocker ARB 54 pentoxifylline 54 metastatic neuroendocrine tumors 54 GRNCM1 54 lipid elevations 54 psychiatric comorbidity 54 NMDA antagonists 54 infarctions 54 T2 lesions 54 MYCN amplification 54 impaired cognition 54 chronic hepatitis cirrhosis 54 poststroke 54 opioid dependent 54 serum testosterone 54 predisposing factor 54 hypothalamic pituitary 54 androgen ablation 54 Erythropoietic therapies may 54 mL/min/#.# m 2 54 HGPIN 54 CYP#D# inhibitor 54 serum IGF 54 plasma homocysteine 54 irbesartan 54 cerebrovascular accident 54 decompensation 54 hypertension diabetes mellitus 54 flutamide 54 coronary artery atherosclerosis 54 infarct size 54 calcified plaques 54 HER2 expression 54 paclitaxel eluting stents 54 prognostic indicators 54 mTOR inhibitors 54 serum concentrations 54 fetal malformations 54 hypoxemia 54 anxiolytic 54 Eisenmenger syndrome 54 triglyceride lowering 54 intima media thickness 54 ALB # 54 EFFEXOR XR 54 neurologic deficits 54 Atypical antipsychotics 54 obstructive coronary artery 54 ABCB1 54 microvascular dysfunction 54 hepatorenal syndrome 54 antirheumatic 54 scintigraphic 54 TOP2A 54 arterial thickening 54 ventricular repolarization 54 metabolizer 54 platelet activation 54 Adjuvant therapy 54 intracoronary 54 venous thromboembolic disease 54 fibrinolysis 54 onset atrial fibrillation 54 certolizumab 54 infarcts 54 HbF 54 Ischemic 54 dyssynchrony 54 oral anticoagulation 54 endometrial hyperplasia 54 Venous thromboembolism 54 Dronedarone 54 systemic corticosteroids 54 NATRECOR ® 54 angiotensin II receptor blockers 54 carotid artery intima media 54 experimentally induced 54 methotrexate monotherapy 54 comorbid psychiatric 54 neutropenia dehydration dyspnea 54 pCR 54 Multivariate analysis showed 54 Ivabradine 54 anterior temporal 54 primary hyperparathyroidism 54 poststroke depression 54 amnestic MCI 54 histological subtype 54 adriamycin 54 MMSE score 54 hypercholesterolemia 54 Hyperlipidemia 54 pegaptanib 54 HbA1c levels 54 intensive statin therapy 54 hypoglycaemic episodes 54 familial hypercholesterolemia 54 ischemic cardiac 54 VMAT2 54 statistically significant predictor 54 recurrent atrial fibrillation 54 Aortic stenosis 54 psychosocial functioning 54 metastatic uveal melanoma 54 oxcarbazepine 54 Haptoglobin 54 serum lipid levels 54 idarubicin 54 μmol L 54 basal cell carcinoma BCC 54 intracranial hemorrhage ICH 54 anticlotting drugs 54 HPA axis suppression 54 hyperosmolar 53 electrical cardioversion 53 INVEGA ® 53 hypothalamic amenorrhea 53 antihyperglycemic 53 atherosclerotic coronary 53 angina pectoris 53 pathologic fractures 53 hemodynamically stable 53 renal impairment 53 kidney insufficiency 53 cardiopulmonary bypass surgery 53 cinacalcet 53 status epilepticus 53 comorbid anxiety 53 NIDDM 53 GnRH agonist 53 prothrombotic 53 myocardial necrosis 53 thromboembolism 53 left ventricular LV 53 stable angina 53 Atherosclerotic 53 leukocyte counts 53 incomplete revascularization 53 QRS interval 53 ziprasidone 53 Fully Covered Stent 53 PRADAXA 53 clazosentan 53 renoprotective 53 biliary tract cancer 53 otamixaban 53 antithrombotics 53 abnormal lipids 53 complete cytogenetic response 53 cytostatic 53 antidepressant efficacy 53 diastolic blood pressures 53 portal venous 53 % CI #.#-#.# [007] 53 atherosclerotic lesions 53 agonist induced 53 myocardial reperfusion 53 metaplasia 53 intrahepatic 53 morphometric vertebral fractures 53 hepatic enzymes 53 lung edema 53 prognostic significance 53 metabolic dysregulation 53 leukoencephalopathy 53 echocardiographic 53 fondaparinux 53 intravesical therapy 53 sequela 53 ischemic lesions 53 Atrial fibrillation AF 53 carotid intima media 53 myocardial infarct 53 Tardive dyskinesia 53 radioiodine therapy 53 ECG abnormalities 53 cardiac toxicity 53 Cypher Stent 53 gadolinium enhanced 53 biliary obstruction 53 tolterodine 53 tirofiban 53 HbA1C levels 53 ipsilateral stroke 53 oral antidiabetic drugs 53 cardiac biomarkers 53 baroreflex 53 neurodevelopmental outcome 53 beta blockers ACE inhibitors 53 octreotide LAR 53 terazosin 53 aminotransferase levels 53 tricuspid regurgitation 53 VaD 53 hepatotoxicity 53 hyperplastic 53 baroreceptor 53 elevated triglycerides 53 HMG CoA reductase inhibitors 53 hepatic toxicity 53 dosing frequency 53 virological response 53 TEAEs 53 unstable angina pectoris 53 blood clot dissolving 53 venous thromboembolic events 53 nocturnal hypoglycemia 53 elevated ALT 53 skeletal metastases 53 anti angiogenic agents 53 atherosclerotic progression 53 lymphocyte counts 53 quetiapine Seroquel 53 PsA 53 lipid lowering medication 53 Valsartan 53 monophasic 53 #beta estradiol 53 divalproex sodium 53 lipid lowering agents 53 intracerebral hemorrhage ICH 53 angina chest 53 prognostic variables 53 Candesartan 53 cardioprotective effect 53 carcinomatosis 53 Aldosterone 53 acute hepatic 53 ARVD 53 EXJADE 53 esophageal gastric 53 Myocardial infarction 53 primidone 53 amenorrhoea 53 serum triglyceride 53 serum bicarbonate 53 myocardial perfusion 53 ventricular hypertrophy 53 antithrombotic 53 aneurysmal subarachnoid hemorrhage 53 GISTs 53 atrial pacing 53 TNF antagonist 53 APOE e4 53 vWD 53 elevated triglyceride levels 53 Darapladib 53 postoperative atrial fibrillation 53 serum magnesium 53 QTc interval 53 gene polymorphism 53 Legg Calvé Perthes disease 53 Lucentis ranibizumab Genentech 53 elevated creatinine 53 completely resected 53 thiazide 53 variceal 53 QTc 53 acute ischemia 53 cTnT 53 Brugada syndrome 53 teratogenic 53 triglyceride concentrations 53 myocardial infraction 53 serum phosphorous 53 platelet reactivity 53 Prehypertension 53 4mg/kg 53 thromboprophylaxis 53 balloon valvuloplasty 53 ejection fraction EF 53 antiarrhythmic agents 53 pacemaker implantation 53 bradycardia 53 primary ovarian insufficiency 53 hypercoagulable 53 oral anticoagulation therapy 53 hydroxymethyl coenzyme 53 salivary flow 53 heart arrhythmias 53 revascularizations 53 postoperative chemotherapy 53 antimetabolite 53 Thrombocytopenia 53 lupus nephritis 53 serum potassium 53 Multivariate analyzes 53 5-fluorouracil/leucovorin 53 sodium nitroprusside 53 rheumatoid factor 53 embolic stroke 53 postoperative delirium 53 hyperglycaemia 53 neovascular glaucoma 53 Venlafaxine 53 DMARD 53 indolent lymphomas 53 vasodilatory 53 antiepileptic drugs AEDs 53 adrenoceptor 53 plasma leptin 53 neuroleptics 53 conventional DMARDs 53 HLA B# 53 endothelial activation 53 nitrofurantoin 53 SCr 53 #β estradiol 53 ranitidine Zantac 53 prospectively randomized 53 macrovascular events 53 immunomodulation 53 acute psychosis 53 coronary artery stenosis 53 Avandia Actos 53 ADHF 53 CMV infection 53 myeloablative 53 hyperintensities 53 LV hypertrophy 53 phototoxicity 53 intravascular ultrasonography 53 proximal DVT 53 improves glycemic 53 adrenergic agonists 53 lowest tertile 53 chronic periodontitis 53 nocturnal hypoglycaemia 53 arbaclofen 53 Alzheimer Disease AD 53 torsades de pointes 53 coronary occlusion 53 coronary calcification 53 pulmonary vasculature 53 lipid lowering therapy 53 Suicidal ideation 53 proinflammatory cytokine 53 Non inferiority 53 rituximab monotherapy 53 null responder 53 FDA defined valvulopathy 53 cardiovascular hospitalizations 53 cerebral angiography 53 serum ALT 53 N telopeptide 53 neurologic symptoms 53 excitotoxic 53 epithelial ovarian cancer 53 angiogenic therapy 53 adenomatous 53 nonfatal myocardial infarction MI 53 SSRI citalopram 53 preoperative PSA 53 confidence interval #.#-#.# 53 lymphadenopathy 53 inotropic therapy 53 thiazolidinediones TZDs 53 nonfatal stroke 53 myocardial infarction 53 basal cell nevus syndrome 53 lipid lowering therapies 53 symptomatic carotid stenosis 53 myocardial contractility 53 hyperbilirubinemia 53 inflammatory biomarkers 53 nicotinic receptor 53 cholecystitis 53 deferiprone 53 dose dependently 53 omnicef 53 Pemetrexed 53 colorectal neoplasms 53 Hypoglycaemia 53 cutaneous melanoma 53 perimenopausal women 53 XZK 53 DU #b 53 NSAID induced 53 Pulmonary hypertension 53 arterial inflammation 53 calcineurin inhibitor 53 rosuvastatin Crestor 53 HOMA IR 53 latent celiac disease 53 ivabradine 53 locoregional recurrence 53 comorbid conditions 53 muscarinic 53 arterial occlusion 53 attain statistical significance 53 hsCRP 53 pituitary hormone 53 advanced adenoma 53 multivariate adjustment 53 Telmisartan 53 endothelial dysfunction 53 NMIBC 53 SIADH 53 arterial stiffness 52 pioglitazone HCl 52 obscure gastrointestinal bleeding 52 colorectal neoplasia 52 decompensated cirrhosis 52 invasive ductal 52 Hp2 2 52 VIIBRYD